Clinical Report: An Overview of Hot Flashes: Clinical Insights and Management Strategies

Overview

Hot flashes affect over 75% of women during menopause. Management strategies include hormone replacement therapy and non-hormonal options, tailored to individual patient needs.

Background

Hot flashes are the most common vasomotor symptom of menopause, impacting a large population of women and men undergoing certain therapies. Understanding the clinical presentation and management of hot flashes is crucial for improving patient care.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Hot flashes are characterized by episodic heat sensation, flushing, and sweating.
• Over 75% of women experience hot flashes during menopause.
• Hormone replacement therapy is the most effective treatment for appropriate candidates.
• Non-hormonal pharmacologic options include neurokinin-targeted antagonists.

Clinical Implications

Management of hot flashes should be individualized based on symptom severity and patient preferences.

Conclusion

Hot flashes require a comprehensive approach to management, considering both immediate symptom relief and long-term health implications.

Related Resources & Content

1. The ASCO Post, 2019 -- Oxybutynin: A Novel Option for Managing Hot Flashes?
2. The ASCO Post, 2011 -- Comparing Therapies for Managing Hot Flashes in Women with Breast Cancer
3. Nature Reviews Endocrinology -- Risk factors, management and consequences of severe menopausal vasomotor symptoms
4. The ASCO Post — Oxybutynin: A Novel Option for Managing Hot Flashes? MANAGING HOT FLASHES Related Articles
5. The ASCO Post — Acupuncture for the Management of Hot Flashes
6. IMS Recommendations on Menopausal Hormone Therapy
7. Risk factors, management and consequences of severe menopausal vasomotor symptoms | Nature Reviews Endocrinology
8. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study - ScienceDirect
9. Elinzanetant for Vasomotor Symptoms Associated With Menopause
10. MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms (hot flushes) caused by menopause   - GOV.UK
11. Lynkuet | European Medicines Agency (EMA)
12. Drug Trials Snapshots: LYNKUET | FDA
13. Fezolinetant▼(Veoza): risk of liver injury; new recommendations to minimise risk - GOV.UK
14. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause